Skip to main content
Clinical Trials/NCT03175640
NCT03175640
Completed
Not Applicable

Implementation to Motivate Physician Response to Opioid Dependence in HIV Settings

Baystate Medical Center2 sites in 1 country294 target enrollmentJuly 12, 2017

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Opioid-Related Disorders
Sponsor
Baystate Medical Center
Enrollment
294
Locations
2
Primary Endpoint
Change in naloxone prescribing behavior
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

The U.S. is in the midst of an epidemic of opioid overdose deaths. The common use of opioids among persons living with HIV, along with their common use of benzodiazepines, has resulted in high rates of opioid overdose among this population. This study will test the implementation of evidence-based training, mentoring, technical support, and academic detailing to encourage HIV physicians to adopt evidence-based interventions to reduce overdose risk and treat opioid addiction.

Registry
clinicaltrials.gov
Start Date
July 12, 2017
End Date
December 31, 2019
Last Updated
5 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Peter Friedmann

Chief Research Officer and Endowed Chair for Clinical Research

Baystate Medical Center

Eligibility Criteria

Inclusion Criteria

  • Clinicians and staff of HIV practice sites that:
  • Receive Ryan White Funding;
  • Treat adults with HIV;
  • Have 3 or more prescribing clinicians;
  • Have an electronic medical record (EMR) with an electronic medication list.

Exclusion Criteria

  • Sites located in states with fewer than 500 Persons Living With HIV (PLWH) will be excluded

Outcomes

Primary Outcomes

Change in naloxone prescribing behavior

Time Frame: baseline to 6 months

Number of clinicians that prescribe naloxone. This information will be collected from electronic medical record (EMR) data.

Secondary Outcomes

  • Change in perception about pharmacotherapy for opioid use disorder; 6-month(baseline to 6 months)
  • Change in prescribing motivation; 6 months(baseline to 6 months)
  • Change in buprenorphine prescribing behavior(baseline to 12 months)
  • Change in prescriber training(baseline to 12 months)
  • Change in perception about pharmacotherapy for opioid use disorder; 12-month(baseline to 12 months)
  • Change in prescribing motivation; 12 months(baseline to 12 months)

Study Sites (2)

Loading locations...

Similar Trials